{"title":"芬尼酮治疗2型糖尿病慢性肾病","authors":"S. Chaplin","doi":"10.1002/psb.2072","DOIUrl":null,"url":null,"abstract":"Finerenone (Kerendia) is a mineralocorticoid‐receptor antagonist for the treatment of chronic kidney disease in patients with type 2 diabetes. This article discusses its indications, efficacy and adverse effects.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"14 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Finerenone for chronic kidney disease in type 2 diabetes\",\"authors\":\"S. Chaplin\",\"doi\":\"10.1002/psb.2072\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Finerenone (Kerendia) is a mineralocorticoid‐receptor antagonist for the treatment of chronic kidney disease in patients with type 2 diabetes. This article discusses its indications, efficacy and adverse effects.\",\"PeriodicalId\":88184,\"journal\":{\"name\":\"The Prescriber\",\"volume\":\"14 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/psb.2072\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2072","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Finerenone for chronic kidney disease in type 2 diabetes
Finerenone (Kerendia) is a mineralocorticoid‐receptor antagonist for the treatment of chronic kidney disease in patients with type 2 diabetes. This article discusses its indications, efficacy and adverse effects.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
